



Our reference:
RIS 31350/8093
EudraCT Number:
2007-006749-42

0115 9515679
paul.cartledge@nottingham.ac.uk

Clinical Trials Unit, MHRA
Market Towers
1 Nine Elms Lane
London
SW8 5NQ

Prof Philip Bath, Chief Investigator
Professor of Stroke Medicine
University of Nottingham
Division of Stroke Medicine
City Hospital Campus
Nottingham
NG5 1PB

13th August 2008

Dear sir or madam,

Sponsorship Statement

Re: Safety and tolerability of clopidogrel when added to aspirin and dipyridamole in high risk patients with recent ischaemic stroke: a randomised controlled trial.

I can confirm that this research proposal has been discussed with the Chief Investigator and agreement to sponsor the research is in place.

An appropriate process of scientific critique has demonstrated that this research proposal is worthwhile and of high scientific quality.*

Any necessary indemnity or insurance arrangements will be in place before this research starts. Arrangements will be in place before the study starts for the research team to access resources and support to deliver the research as proposed.

Arrangements to allocate responsibilities for the management, monitoring and reporting of the research will be in place before the research starts.

The duties of sponsors set out in the NHS Research Governance Framework for Health and Social Care will be undertaken in relation to this research.**

I authorise the Chief Investigator to act on behalf of the Sponsor in this application.

* Not applicable to student research (except doctoral research).

** Not applicable to research outside the scope of the Research Governance Framework.

Yours faithfully

Paul Cartledge

Head of Research Grants and Contracts
University of Nottingham